Faculty across 4 institutions discuss their participation in a 4-team initiative launched by Stand Up To Cancer® that focuses on expanding access to cancer care and research.
To expand access to cancer care and research, Stand Up to Cancer® has launched a 4-team initiative across the United States designed to fill in these gaps in care and remove barriers to entry.
In the phase 3 PRESTO trial, men with high-risk biochemically recurrent prostate cancer received intensified ADT with apalutamide, with or without abiraterone plus prednisone, for 1 year.
In the phase 3 PRESTO trial, men with high-risk biochemically recurrent prostate cancer received intensified ADT with apalutamide, with or without abiraterone plus prednisone, for 1 year.